The Osteoporosis Program, which is co-directed by Ruban Dhaliwal, MD, MPH and Jennifer Kelly, DO, FACE, provides patients in Central and Northern New York a uniquely comprehensive approach to the evaluation and management of osteoporosis and other metabolic bone diseases including osteoporosis imperfecta and Paget's disease. Our disciplinary team consists of adult and pediatric endocrinologists, osteoporosis nurse educators, an exercise physiologist, and a state of the art bone density (DXA) machine with a dedicated certified DXA technician. A PhD research scientist provides valuable input into our evaluations of difficult cases.
The Osteoporosis Program is recognized by the National Osteoporosis Foundation as a member of the Professional Partners Network. The Network assists our local group to provide accurate, timely information to patients, family members, at-risk individuals and the general public. Our educational programs are designed to increase awareness and knowledge of osteoporosis prevention, diagnosis and treatment by conducting on and off site community outreach conferences, health fairs and employee wellness programs.
As an Upstate Medical Center facility, the physicians in the Program conduct clinical research projects on patients with metabolic bone problems on the Upstate Clinical Research Unit at the Institute of Human Performance.
Phase III Studies of Pharmaceutical Agents in the Treatment of Postmenopausal Osteoporosis.
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Women with postmenopausal osteoporosis, with and without fractures, are being followed in placebo controlled double blind multicenter protocols. The primary parameters of efficacy are bone density and incidence of new fractures. The agents currently being tested are the selective estrogen receptor modulator, raloxifene, and the bisphosphonate, alendronate. The current emphasis with raloxifene is to determine possible long term adverse actions. Alendronate is being administered intermittently to determine if this dosing regimen, which should be more acceptable to patients, is as effective as daily dosing in the prevention and treatment of osteoporosis.
Moses, A.M., Thomas, D.G., Canfield, M.C., Collins, G.H.: Central diabetes insipidus due to cytomegalovirus infection of the hypothalamus in a patient with AIDS: A clinical, pathological and immunohistochemical case study. J. Clin. Endocrinol. Metab. 88: 51-54, 2003.
Kelly, J.J., Moses, A.M: Osteoporosis in men: the role of testosterone and other sex-related factors. Curr Opin Endocrinol and Diabetes 12:452-458, 2005.
Weinstock, M.A., Moses, A.M. Skin cancer meets vitamin D: The way forward for dermatology and public health. J. Am. Acad. Dermatol. 61: 720-724,2009.